麦格理研报指出，维他奶2024下半财年销售额内生增长达到6%，对比上半财年取得3%跌幅，相信主要来自于内地业务改善及香港业务表现强韧，有助抵销新西兰业务的负面影响。予维他奶国际“跑赢大市”评级，应最新业绩表现及宏观经济前景，将2025至2026财年净利润预测分别下调8.8%及9.6%，目标价从10.5港元下调至9.5港元。Vitasoy int'l (00345) fell over 4%. As of press time, it decreased by 4.24% to HKD 6.1 with a turnover of HKD 4.1571 million.
According to the Zhixin Finance & Economics App, Vitasoy int'l (00345) fell over 4%. As of press time, it decreased by 4.24% to HKD 6.1 with a turnover of HKD 4.1571 million.
On the news front, Vitasoy int'l recently released its annual results as of the end of March this year, with revenue of HKD 6.217 billion, a year-on-year decrease of 2%; net income of HKD 116 million, a year-on-year increase of 154.5%; and earnings per share of 10.9 HK cents. The final dividend is 6.3 HK cents, together with an interim dividend of 1.4 HK cents per share, for a total dividend of 7.7 HK cents per share for the year, compared with a total dividend of 2.7 HK cents per share for the previous fiscal year. During the reporting period, compared with the overall performance of the Chinese market, Vitasoy int'l underperformed in the international market, with revenue from Australia and New Zealand totaling HKD 530 million and a loss of over HKD 80 million.
According to the Macquarie research report, Vitasoy is expected to achieve a 6% increase in organic sales growth in the second half of fiscal year 2024, compared with a 3% decline in the first half of the fiscal year. This is believed to be mainly due to the improvement in the mainland business and the strong performance of the Hong Kong business, which will help offset the negative impact of the New Zealand business. Vitasoy International is rated as "outperforming the market." Based on the latest performance and macroeconomic outlook, net profit forecasts for fiscal years 2025 and 2026 have been lowered by 8.8% and 9.6%, respectively, and the target price has been lowered from HKD 10.5 to HKD 9.5.